Condition: Colorectal Cancer · Stomach Cancer · Pancreatic Cancer · Sponsor: Weijia Fang, MD
This is a phase I clinical study to evaluate the safety and tolerability of FAST targeted chimeric antigen receptor (CAR)-T cells (PTC13) in patients with carcinoembryonic antigen (CEA)-positive advanced malignant solid tumors, and to obtain the maximum tolerated dose of FAST CAR-T (PTC13) and phase II Recommended dose.
This description comes directly from the study's public registry record.
Weijia Fang, MD · 86-0571-87237587 · weijiafang@zju.edu.cn
Yang Gao, MD · gaoyang954@zju.edu.cn
Always discuss trial participation with your own doctor first.
| the First Affiliated Hospital, Zhejiang University School of Medicine (FAHZU) | Hangzhou, Zhejiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06821048